UNDERWRITING AGREEMENTUnderwriting Agreement • September 9th, 2015 • Strongbridge Biopharma PLC • Pharmaceutical preparations • New York
Strongbridge Biopharma plc, an Irish public limited company (registered no. 562659) (the “Company”), confirms its agreement with Merrill Lynch, Pierce, Fenner & Smith Incorporated (“Merrill Lynch”), Stifel, Nicolaus & Company, Incorporated (“Stifel”) and each of the other Underwriters named in Schedule A hereto (collectively, the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 10 hereof), for whom Merrill Lynch and Stifel are acting as representatives (in such capacity, the “Representatives”), with respect to (i) the issue by the Company and the subscription by the Underwriters, acting severally and not jointly, of the respective numbers of Ordinary Shares of the Company, par value $0.01 per share (“Ordinary Shares”), set forth in Schedule A hereto and (ii) the grant by the Company to the Underwriters, acting severally and not jointly, of the option described in Section 2(b) hereof to subscribe for all or any part of [·] addi
